The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Low FODMAP dietary regimen: intervention will include a guidance by a clinical dietitian about low FODMAP diet The FODMAP diet has three phases: 1. Elimination - Avoidance from high-FODMAP foods (2-6 weeks) 2. Reintroduction -Structured challenges of specific food groups each time (6-8 weeks). 3. Maintenance - personalized diet, according to the response in step 2.

Study summary

Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. The two main mechanisms invoking IBS development and flares include 1) an increase in luminal water content due to malabsorption of small molecules and 2) incrementation of colon gas production generated by the fermentation of small molecules by gut bacteria.Yet to date, a person-specific elucidation of the specific small molecules and bacteria driving IBS, and their downstream effects on the human gut epithelium remain unknown.

Over the past years, it became evident that dietary regimes, and their interactions with the intestinal microbiome, are at the center of IBS symptom generation and alleviation. The most widely used dietary intervention is a highly restrictive diet, the low-Fermentable Oligo-saccharides Di-saccharides Mono-saccharides And Polyols (FODMAP) diet, based on avoidance of multiple food items that contain available fermentable molecules.

The low-FODMAP diet remains an effective line of treatment for IBS patients, yet due to its complexity and unhealthy nature, it remains a last line of treatment and fails to impact the majority of IBS patients.

Eligibility

Primary outcome measure(s)

• IBS-SSS - irritable bowel syndrome severity score system questionnaire — 1 week
  Severity of symptoms as they are scored in the Rome IV IBS-SSS 75 to \<175 to indicate mild IBS, 175 to \<300 as moderate, and \>300 as severe
• IBS-QOL questionnaire - irritable bowel syndrome quality of life questionnaire — 1 week
  Quality of life scores from the Rome IV IBS-QOL 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life

Trial sites (1)

More Weizmann Institute of Science trials in Israel